CSTLCastle Biosciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +16% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CSTL is trading
Castle Biosciences, Inc. is +47% over the past year while the S&P 500 is +18%: 29 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +16%
vs 200-day average · a clear uptrend
- RSI (14)
- 42
RSI (14) · neutral
- Below its 52-week high
- 22%
Below its 52-week high
Details›
- Last close2026-10-08
- $33.72
- 1 monthS&P 500 +1.6%
- +4.3%
- 1 yearS&P 500 +18%
- +47%
- 5 yearsS&P 500 +86%
- −49%
- vs 50-day average$33.12
- +1.8%
- 52-week high
- $43.04
- 52-week low
- $18.15
- Annualised volatility
- 59%
| Year | Return |
|---|---|
| 2026 (year to date) | −13% |
| 2025 | +46% |
| 2024 | +23% |
| 2023 | −8.3% |
| 2022 | −45% |
| 2021 | −36% |
| 2020 | +95% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 5 of 7 | +2.8% |
| Feb | 7 | 2 of 7 | −9.4% |
| Mar | 7 | 2 of 7 | −2.7% |
| Apr | 7 | 3 of 7 | −7.3% |
| May | 7 | 3 of 7 | −0.75% |
| Jun | 7 | 3 of 7 | +1.4% |
| Jul | 7 | 5 of 7 | +7.3% |
| Aug | 8 | 8 of 8 | +24% |
| Sep | 8 | 2 of 8 | −7.8% |
| Oct | 8 | 3 of 8 | +4.0% |
| Nov | 7 | 4 of 7 | +6.8% |
| Dec | 7 | 4 of 7 | +9.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
Ranks #11 of 21 by RyuScore